• News
  • IO Biotech presented posters on preclinical studies at SITC Annual Meeting

IO Biotech presented posters on preclinical studies at SITC Annual Meeting

Copenhagen, Denmark – November 13, 2017: IO Biotech announced that two posters summarizing recent preclinical findings in the company’s leading products, IO102 and IO103, were exhibited over the weekend at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, held in National Harbor, Maryland.

“The data presented here reveal the important MoA of our vaccine, namely that the vaccine confers anti-tumor immunity by targeting the tumor microenvironment. Furthermore the vaccine works in synergy with checkpoint mAb – we look forward to testing this further in our clinical development programme” said Mads H Andersen, CSO.

Please find both posters here:

Preclinical In Vivo Model Validation for the Development of a Novel Vaccine Based Strategy Targeting IDO1

PD-L1-specific T cells are activated by inflammation and can readily be expanded by epitope vaccination